Search

Displaying results 3571 - 3580 of 9865 in total
  1. Drug

    Digoxin

    go.drugbank.com/drugs/DB00390
    ApprovedInvestigational

    [A178225] It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. … [A178234] Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954.

    Categories: BSEP/ABCB11 Substrates with a Narrow Therapeutic Index, P-glycoprotein substrates with a Narrow Therapeutic Index
  2. Drug

    PF-03187207

    go.drugbank.com/drugs/DB05746
    Investigational

    PF-03187207 is a nitric oxide-donating prostaglandin F2-alpha analogs for the potential treatment of glaucoma. … The development of abnormally high IOP, due to blockage or malfunction of systems controlling the amount of fluid in the eye, is believed to be one of the principal causes of glaucoma.

  3. Drug

    Rivanicline

    go.drugbank.com/drugs/DB05855
    Experimental

    Rivanicline also has stimulant and analgesic actions which are thought due to increased noradrenaline release. … It has subsequently been developed as a potential anti-inflammatory treatment for ulcerative colitis.

  4. Drug

    AIT-034

    go.drugbank.com/drugs/DB06106
    Experimental

    AIT-034 is a distinct chemical analog of hypoxanthine and pyrollidone that has been demonstrated in animal studies to enhance memory and to reverse memory deficits in severely impaired animals that do … There is some evidence that AIT-034 could complement Neotrofin as a treatment for Alzheimer's disease and dementia.

  5. Drug

    Moroctocog alfa

    go.drugbank.com/drugs/DB13999
    Approved

    is a fully recombinant factor VIII-Fc fusion protein which has an extended half-life compared with conventional factor VIII due to conjugation to the dimeric Fc domain of human immunoglobulin G1, a long-lived … Also known as Anti-Hemophilic Factor (AHF), endogenous Factor VIII is essential to the clotting process in the body due to its involvement in the clotting cascade where it is responsible for acting as

    Products: Xyntha 250 IU Powder and Solvent for Solution for Injection, Xyntha 1000 IU Powder and Solvent for Solution for Injection
  6. Drug

    VPM1002

    go.drugbank.com/drugs/DB15801
    Investigational

    BCG versions due to the lack of the RD2 genome segment. … VPM1002 is a recombinant BCG vaccine candidate expressing listeriolysin and deficient in urease that is generated in the genetic background of BCG Prague as it has a better safety profile than some other

  7. Drug

    CX-052075

    go.drugbank.com/drugs/DB31655
    Approved

    CX-052075 is a nucleoside-modified messenger RNA (mRNA) encoding the N-terminal domain (NTD) and receptor-binding domain (RBD) of the spike glycoprotein of the SARS-CoV-2 Omicron variant sublineage LP.8.1 … [L53408,L53423] The original approval was formulated with the JN.1 strain ([mRNA-1283]), but was ultimately updated to the sublineage LP.8.1.[L54586]

  8. Drug

    Ubrogepant

    go.drugbank.com/drugs/DB15328
    ApprovedInvestigational

    [A189195] They appear to be better tolerated, do not contribute to medication overuse headaches, and carry no apparent cardiovascular risk, making them suitable for use in patients with cardiovascular … [L10959] Several oral small molecule CGRP receptor antagonists, belonging to a class of medications referred to as "gepants", have been investigated for migraines, but only ubrogepant and [rimegepant]

    Categories: Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  9. Drug

    Influenza B virus B/Austria/1359417/2021 recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB16923
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that helps to protect against infection from influenza viruses.

  10. Drug

    Influenza A Virus A/California/122/2022 SAN-022 (H3N2) antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB18750
    Approved

    Recombinant influenza vaccines are produced by synthesizing recombinant influenza hemagglutinin antigen in a laboratory and do not require the use of candidate viruses or egg-based manufacturing processes … A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that helps to protect against infection from influenza viruses.

    Synonyms: Influenza A Virus A/California/122/2022 SAN-022 (H3N2) antigen (formaldehyde inactivated)Categories: Inactivated Influenza A Virus Vaccine